iFAST gets premium valuation in analyst report by Jefferies set Target Price of S$4.35 and “Buy” Rating

Although the last decade has seen robotics starting to infiltrate, the Covid-19 pandemic looks set to accelerate adoption. As doctors and nurses are under tremendous pressure to deliver care under hazardous conditions, robotics is offering a safer way to augment and replace human tasks.